Developing an adaptive radiotherapy technique for virally mediated head and neck cancer by Brown, Elizabeth et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Brown, Elizabeth, Proceddu, Sandro, Owen, Rebecca, & Harden, Fiona
(2013) Developing an adaptive radiotherapy technique for virally mediated
head and neck cancer. Journal of Medical Imaging and Radiation Sci-
ences, 44, pp. 135-141.
This file was downloaded from: http://eprints.qut.edu.au/62195/
c© Copyright 2013 Elsevier
This is the author’s version of a work that was accepted for publication
in Journal of Medical Imaging and Radiation Sciences. Changes result-
ing from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be re-
flected in this document. Changes may have been made to this work since
it was submitted for publication. A definitive version was subsequently
published in Journal of Medical Imaging and Radiation Sciences, [VOL 44,
(2013)] DOI: 10.1016/j.jmir.2013.04.001
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1016/j.jmir.2013.04.001
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
DEVELOPING AN ADAPTIVE RADIOTHERAPY TECHNIQUE FOR VIRALLY 
MEDIATED HEAD AND NECK CANCER 
 
Elizabeth Brown MHealthSc (MRS)1,4, Sandro Porceddu MD, FRANZCR 1, 2, 
Rebecca Owen PhD3, Fiona Harden PhD4 
 
1Radiation Oncology Department, Princess Alexandra Hospital, Brisbane, 
Queensland, Australia 
2School of Medicine, University of Queensland, Brisbane, Queensland, Australia 
3Radiation Oncology Department, Radiation Oncology Mater Centre, Brisbane, 
Queensland, Australia 
4Queensland University of Technology, Brisbane, Queensland, Australia 
 
Correspondence 
Elizabeth Brown 
Department of Radiation Oncology 
Princess Alexandra Hospital 
Ipswich Road 
WOOLLOONGABBA QLD 4102 AUS 
Email address: elizabeth@mebrown.net 
Facsimile no.: +61731766127 
Telephone no.: +61731766586 
 
Keywords; head and neck, radiotherapy, adaptive, viral 
*2) Title Page (with author identifiers)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 1 
Introduction 
Clinical investigation over the past 2 decades has produced an increased 
recognition of the etiological links between particular viruses and certain head 
and neck cancers. The association between nasopharyngeal cancer (NPC) and 
increased expression of the Epstein Barr Virus (EBV) has long been established 
[1].  Recent studies have demonstrated a causal association between 
oropharyngeal squamous cell carcinoma (OSCC) and infection with the Human 
Papillomavirus (HPV), particularly the p16 strain of the virus [2, 3].  These 
VMHNC’s collectively represent a subset of cancers with a distinct clinical entity 
[4]. Compared with traditional head and neck cancers they generally have 
greater likelihood of response to therapy, are not necessarily related to smoking, 
have a more favourable prognosis and have a different pathway of malignant 
transformation [5].  For this reason the investigators agreed that it would be 
appropriate to study both virally mediated NPC and OSCC.  As many of these 
patients are long-term survivors, reducing the burden of treatment-related toxicity 
is paramount.  This can be achieved by further minimizing the dose delivered to 
surrounding functional healthy tissue.  Adaptive radiotherapy (RT) is one strategy 
to reduce treatment-related acute and long-term toxicity. 
 
Adaptive RT is an approach to correct for various geometric variations that occur 
during  a  patient’s  treatment  [6].    It  includes  repeated  image-based modification of 
treatment delivery and the adjustment of the treatment plan to account for 
changes in the  patient’s  anatomy  during  the  treatment  period  [2,  3].    Anatomical  
*3) Blinded Manuscript / Column (without author identifiers)
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 2 
changes include primary tumour and/or nodal shrinkage and weight loss [7]. 
Techniques such as intensity modulated radiotherapy (IMRT) highlight the 
importance of adaptive planning due to the potential impact induced by 
anatomical changes on these highly conformal dose distributions with steep dose 
gradients [6].  
 
Methodology for dealing with treatment-induced anatomical changes has typically 
relied on the clinical judgment of the treating Radiation Therapists.  To date, no 
standardized indicator for asymmetric anatomical changes exists which adds to 
the difficulty of streamlined treatment adaptation.  
 
This study is a retrospective review of patients with virally mediated head and 
neck cancer (VMHNC), who attended the Princess Alexandra Hospital (PAH) for 
definitive RT between 2005 and 2010.  It was undertaken to assess the 
characteristics of patients who respond well during a radiotherapy treatment 
course to identify specific predictive factors that could determine which patients 
will benefit most from adaptive RT.  This information is valuable in forming the 
basis of a standardized approach to pre-emptively manage this group to ensure 
benefit to the patient and optimal use of departmental resources.  The primary 
aim was to develop potential risk profiles and associated adaptive management 
strategies that would be most effective for these patients. It was hypothesized 
that the need for adaptive intervention is related to the dominant nodal size at 
diagnosis.  
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Methods and Materials 
Patients 
Patients with VMHNC who received definitive RT treatment with or without 
systemic therapy, between 2005 and 2010 were identified from a prospective 
head and neck PAH database and retrospectively reviewed.  Eligibility criteria 
included: histologically confirmed NPC or OSCC, with either positive serology for 
EBV or p16 (immunostaining >70%) and node positive disease with any T stage 
disease and treatment plan accessible on the treatment planning system.  
Patient demographics and tumour characteristics (including pre-treatment size of 
the dominant node) were recorded.  Nodal size data was collected from each 
patient’s  diagnosis  and  staging  information.    Treatment  technique  was  also  
recorded as both three-dimensional conformal radiotherapy (3DCRT) and IMRT 
was used during the study period.  The project was approved by the Human 
Research Ethics Committees from the Princess Alexandra Hospital and 
Queensland University of Technology (3rd June, 2011).  
Assessment of adaptive planning interventions 
Treatment techniques employed and associated image guidance protocols 
evolved over the study period.  It incorporated both 3DCRT with weekly 
electronic portal imaging and IMRT with weekly cone beam computed 
tomography (CBCT) imaging.  CBCT replaced the practice of taking of manual 
separations to assess treatment response.  There was no protocol to identify 
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 4 
patients requiring adaptive planning interventions or guidelines on what adaptive 
planning intervention to employ.  Decisions were made based on the treating 
Radiation  Therapists’  judgement  on  a  daily  basis.    However,  if  there  was  a 
change in body contour outline, separation or source-to-skin distance (SSD) 
reading of greater than 1cm, the plan was returned to planning for review for the 
duration of the study.   
 
The adaptive planning interventions used at this time were categorised as 1) 
SSD correction or monitor unit (MU) adjustment as a result of changes in SSD 
readings, 2) Re-CT or performing a second planning computed tomography scan 
and 3) Re-plan or generation of another treatment plan based on the re-CT scan.  
Details of the above 3 interventions, including timing, affected fields, magnitude 
of change as well as weight and volume changes, were recorded. 
 
SSD corrections 
SSD corrections are a planning intervention used in the department to adapt the 
daily dose delivered by a field to match treatment-induced changes in the 
patient’s  separation.  These  are  defined  as  an  adjustment  to  a  field’s  planned  
MUs based on either a change in the daily treatment SSD from the planned SSD, 
or a change in the separation recorded at the time of treatment from the planned 
separation.  Relevant standard separation points (reference point and minimum 
spinal cord separation) were identified for each patient and used for assessment 
of that patient throughout treatment.  This MU adjustment was calculated using a 
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 5 
specially designed, in-house program.  Table 1 shows the input information 
required for each affected field.  An SSD correction was only applied to fields that 
had a change in SSD during treatment.   
 
The dose and fraction at which the separation change occurred as well as the 
difference between the planned and treatment measurements at the reference 
point and minimum spinal cord separation was recorded.  The design of the 
calculation program employed by the department at the time of the study meant 
that corrections were applied to 3DCRT techniques only and not IMRT 
techniques. 
 
Re-CT 
Re-CT was defined as any patient that underwent a second planning CT to 
assess anatomical changes during their treatment course.  This did not include 
cone beam CTs (CBCT) taken on the treatment unit itself.  A re-CT was 
requested based on the clinical judgment of the radiation oncologist or treating 
Radiation Therapists.  A re-CT indicated that the treating Radiation Therapists 
considered  the  patient’s  response  to  treatment had the potential to impact upon 
the treatment plan and warranted further investigation.  It may or may not have 
resulted in an actual adjustment to the treatment. 
 
For those patients that underwent a re-CT, the time, dose and fraction were 
recorded.  If a plan adaption was indicated, no standard protocol existed as to 
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 6 
whether an SSD correction or re-CT was performed.  The reason for the re-CT 
was evaluated in consultation with the treating radiation oncologist by reviewing 
an image registration of the planning CT scan and the re-CT scan on the 
treatment planning system.  This image registration was performed using bony 
anatomy minimising the influence of daily set up variation.  The reason for the re-
CT was categorised into: 1) primary tumour volume regression based on the 
contoured GTV, 2) nodal volume regression, 3) weight loss or a combination of 
these factors.  Patients who underwent a re-CT were further investigated and 
other contributing factors including magnitude of weight loss, primary tumour 
volume regression, nodal tumour volume regression and whether a new RT plan 
was generated were recorded.   
 
Re-plan 
A re-plan involves the generation of a new RT plan calculated on the re-CT data, 
accounting for treatment-induced anatomical changes.  The original target 
volumes may have been re-contoured  based  on  the  radiation  oncologist’s  
observation of the repeat CT scan registered with the planning CT scan.  This 
meant that the re-plan might have used either the original beam arrangement or 
an altered approach.  A verification plan was created for IMRT patients where the 
planned fluence map and MU were applied to the re-CT.  If a re-plan was 
performed, the dosimetric effect was quantified by comparing dose volume 
histograms (DVH) derived from the treatment delivered and the original treatment 
plan of gross target volumes (primary and nodal tumour volumes) and critical 
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 7 
structures.  This comparison allowed the effect of re-planning or adaptive 
treatment management to be evaluated.  
 
Statistics 
Data was analysed using the Stata (version 12.1, StataCorp LP, Texas, USA) 
program. The number and magnitude of adaptive planning interventions were 
identified as well as factors that may contribute to the need for patients to 
undergo a re-CT and/or replan.  Statistical analysis included basic descriptive 
statistics and logistic regression analysis to determine the predictive value of the 
risk profiles.  Classification and regression tree (CART) analysis was used to 
determine the relative contribution of factors such as initial weight, nodal size and 
disease stage to the need for adaptive intervention.  In the regression analyses, 
a p-value of < 0.05 was considered statistically significant.  Risk profiles were 
determined based on the nodal sizes of patients who underwent adaptive 
interventions in comparison to those that did not.    
 
Results 
Patient characteristics 
122 patients out of 221 met the inclusion criteria.  Of the 122 patients identified, 
one patient was excluded due to missing treatment information.  The 
characteristics of the 121 eligible patients can be seen in Table 2.  Patients were 
predominantly male, 105 patients had HPV-positive OSCC and 16 had EBV-
positive NPC cancer.  Forty-six (38%) patients required varying types of plan 
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 8 
adaptation during treatment:  32 (26.4%) had an SSD correction, 25 (20.7%) a 
re-CT and 16 (13.2%) a re-plan.  43.5% of patients underwent multiple adaptive 
interventions with 4 patients undergoing both a re-CT and SSD correction and 7 
patients undergoing a re-plan and SSD correction.  One patient was excluded 
from the dominant nodal size analysis as it was considered an extreme case 
(150mm) and was greater than 4 standard deviations outside the mean.  Table 3 
shows a comparison of patient characteristics for patients requiring a planning 
intervention and those who had no intervention.  Of the 121 patients, 8 were 
treated with an IMRT technique with the remaining patients treated with 3DCRT.   
 
SSD corrections 
Thirty-two (26.4%) patients required an SSD correction to one or more treatment 
fields.  12.5% of patients required 2 to 3 corrections throughout treatment.  SSD 
corrections were performed at a median time point of 26 fractions (range 5-34 
fractions).  This corresponded with the commencement of the second phase of 
3DCRT where field sizes were reduced to cover the high-risk tumour volume.  
The mean dominant nodal size for patients who had an SSD correction was 41 
mm (+/- 14.2 mm).  Details for SSD corrections are given in Table 4. 
 
Re-CT 
Twenty-five (20.7%) patients required a re-CT during their treatment. Table 5 
summarises the characteristics of patients who underwent a re-CT.  No treatment 
plan adaptation was required for 5 of these patients due to the negligible 
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 9 
difference in dose distribution.  This was determined by the radiation oncologist 
and was based on dose volume histograms (DVHs) of target and critical 
structures.  Four of these patients had a SSD correction performed based on the 
information from the re-CT and 16 patients had a re-plan generated.  Re-CTs 
were performed at a median time point of 22 (range 0-29) fractions with one 
patient requiring a re-CT to be performed before the commencement of treatment.  
The mean dominant nodal size for patients who underwent a re-CT was 44.2 mm 
(+/- 21.3 mm).  The most frequently occurring justification for a re-CT was a 
combination of weight loss and dominant nodal regression during treatment.  
Two patients underwent a re-CT for other reasons: one was rescanned due to 
set-up error and one was rescanned to re-plan the lower neck area as directed 
by the treating radiation oncologist. 
 
Re-plan 
Sixteen (13.2%) patients had a re-plan generated during their treatment, 
including 3 IMRT patients.  Of these 16 patients, 3 (18.8%) did not have their re-
plan clinically actioned based on the fact that the DVHs of target and critical 
structures were clinically acceptable.  An SSD correction alone was performed 
on 7 (43.8%) patients and was based on the information from the re-CT only 
instead of employing the re-plan. Treatment adaptation occurred in 6 (37.5%) 
patients.  The majority of clinically actioned re-plans were calculated for 
implementation from fraction 26, the commencement of the second phase of 
treatment.  One re-plan was generated and implemented before the beginning of 
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the  patient’s  treatment  and  one  was  implemented  from  fraction  2.    The  mean  
number of working days between when the re-CT was performed and the 
implementation of the re-plan was 3 (range 1-5) days.  The mean dominant nodal 
size in patients with a re-plan, irrespective of whether it was actioned or not, was 
44.8 mm (+/- 21.5 mm). 
 
Risk profiles 
Based on preliminary evaluation of the adaptive planning intervention required in 
patients with VNHNC, there was a trend toward 3 risk profile groupings: 1) Low 
risk category with minimal need (< 10%) for adaptive treatment management.  
This would include patients with a dominant pre-treatment nodal size of ≤ 35 mm, 
2) Intermediate risk category with a possible need (< 20%) for adaptive treatment 
management.  This would include patients with a dominant pre-treatment nodal 
size of 36 mm – 45 mm and 3) High-risk category with an increased likelihood (> 
50%) for adaptive treatment management.  This would include patients with a 
dominant pre-treatment nodal size of ≥ 46 mm.  The thresholds for these 
groupings were based on a combination of clinical experience and pre-treatment 
dominant nodal size for patients who had a re-CT or re-plan compared with those 
that did not.  Logistic regression models have demonstrated that these groups 
have a 62.5% positive predictive value and an 83% negative predictive value 
when based on pre-treatment nodal size and age.  CART analysis demonstrated 
a relationship between adaptive intervention and pre-treatment nodal size (p-
value <0.001), age (p-value 0.07) and initial weight (p-value 0.05).  It is important 
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to note that a difference or exclusion of a lack of difference between the 3 groups 
could not be detected in data analysis because of the limited sample size.  
Results suggest that performing a re-CT at approximately fraction 20 may be 
beneficial for those in the intermediate and high-risk categories. 
 
Discussion 
Compared  with  traditional  head  and  neck  cancers,  VMHNC’s  tend  to  present  with  
nodal disease, generally have a greater likelihood of response to RT and have a 
more favourable prognosis [5]. This can result in the need to re-plan during 
treatment to maintain adequate coverage of tumour and limit the dose to critical 
structures.  Clinician judgment currently plays a key role in deciding which 
patients require adaptive RT.  The need for a systematic approach to this issue 
and the determination of specific predictive factors has been previously 
highlighted [7, 9, 10].  Due to the variability in response and the dynamic nature 
of the changes that occur throughout treatment to head and neck cancer patients, 
establishing these predictive factors presents a challenge.  As VMHNC patients 
in particular are living longer with the debilitating functional long-term side effects 
of treatment, it was felt that focus was required on which of these patients would 
benefit most from adaptive intervention to further minimize dose to surrounding 
tissues affecting quality of life.  We found that patients with VMHNC and nodal 
size > 46 mm appeared to be a high-risk group that are more likely to be re-
planned during a course of definitive RT.  Those patients who underwent 
adaptive planning intervention had a greater mean dominant node size than 
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those who did not (Table 3).  Barker and colleagues [9] support this observation 
reporting that patients with larger tumours volumes required re-planning during 
their treatment.   
 
Adaptive radiotherapy is an approach to correct for morphological changes in 
patient anatomy including normal tissues and tumour volume variations as a 
result of treatment [6].  It can include both image-based modifications and 
treatment plan adjustments [2].  Image guidance throughout treatment is an 
essential component of adaptive RT.  The planning CT performed before the 
commencement  of  a  patient’s  treatment  only  provides  a  snapshot  of  their  
anatomy at this point in time and does not accurately represent the anatomical 
relationship between clinically important structures that may alter throughout the 
course of treatment [11].  The uncertainty surrounding the position, size and 
shape of normal and critical tissues during treatment has a potentially greater 
impact with the adoption of IMRT as the treatment of choice for these patients 
[11].  IMRT enables the generation of steep dose gradients that allow target 
volumes to be treated to high doses whist minimizing the dose delivered to 
surrounding normal and critical tissues [6].  Consequently, minute changes in 
anatomy can result in dosimetric inaccuracies that produce significant impact on 
surrounding radiosensitive tissues [12].  This is demonstrated in our study where 
4 of the 8 patients treated with IMRT underwent adaptive planning intervention 
and 3 patients had a re-plan generated.  Incorporation of standardized image 
guidance protocols into the adaptive RT strategy developed will enable a 
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systematic approach to monitoring these treatment-induced anatomical changes 
and prompting adaptive intervention.  CBCT may be used to monitor the patient 
daily on the treatment unit however, if a dosimetric adjustment is indicated, a re-
CT is still required for accurate dosimetric calculation.  
 
The findings of this study are consistent with those of other investigations with 
some exceptions.   In a retrospective evaluation of IMRT patients, Jensen and 
colleagues [13] found that 15 of the 72 (20.8%) patients reviewed underwent plan 
adaptation at least once during their treatment compared with 38% for the 
present study.  The larger numbers of adaptive intervention in the present study 
may be a reflection that the majority of patients were treated with 3DCRT 
techniques.  The SSD correction intervention method described and employed 
for patients treated with 3DCRT in this study is unable to be used with IMRT and 
was therefore not utilized in the Jensen study.  Excluding patients who 
underwent an SSD correction, the percentage of patients who had a re-CT in our 
study is comparable to the study by Jensen and his colleagues [13].  It is 
important to note that as IMRT is now the treatment of choice for VMHNC 
patients in our department, the SSD correction method is no longer routinely 
used.  The resultant impact is that there may be a higher percentage of patients 
requiring a re-CT and/or re-plan in the future.  The present study only evaluated 
patients with VMHNC.  The known increased radioresponsiveness of these 
tumours and their classic presentation of large nodes may have contributed to 
the higher percentage of patients requiring intervention in our study.  The 
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 14 
variation between the studies may also be a result of the lack of a systematic 
approach to the use of adaptive interventions during the time of the present study.  
 
The majority of patients involved in this study were treated with 3DCRT as 
opposed to IMRT, however the technique utilized is not critical to the purpose of 
obtaining information on VMHNC treatment response and predictive factors 
indicating which patients will benefit most from adaptive RT.  Consequently, 
these data provide a baseline and establish factors predicting the need for 
adaptive intervention that can be refined and further developed.  The inherent 
risk in retrospective studies, particularly the lack of control over the consistency 
of the data, means that cautious interpretation of the results should be 
undertaken.  Further analysis is required to develop the predictive model.  This 
was a direct result of no existing departmental guidelines on how to identify when 
patients require plan adaption.  However, a baseline for the development of 
appropriate risk profiles for this subgroup of patients has been established so 
that adaptive planning interventions can be determined and acted upon as 
required.  
 
Conclusion 
The use of adaptive radiotherapy techniques are important for VMHNC patients 
to ensure the delivery of the prescribed dose to target volumes whilst minimizing 
the dose to surrounding critical and normal tissues.  The generation of predictive 
factors and associated treatment management guidelines is of particular 
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importance in determining the optimal process for the implementation of adaptive 
treatment planning.  This will provide maximum benefit, in terms of efficacy and 
efficiency, for both patients and busy radiotherapy departments.  A future 
prospective study is currently being designed to validate the findings of the 
present study. 
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Table 1 Information required for SSD correction calculation 
 
Data field 
Beam energy 
Equivalent square field size 
Planned MU 
Planned path length from surface to isocentre at reference point 
New path length from surface to isocentre at reference point# 
Number of fractions change applicable for 
Number of remaining fractions  
# Determined by difference in separation measurement from planning or planned 
SSD from average treatment SSD since change occurred. 
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Table 2 Patient characteristics 
 
  Characteristics 
Sex  
Male 106 
Female 15 
Age mean (range) 54 (22-81) 
Primary tumour site  
Tonsil 65 
Base of tongue 34 
Other 6 
Nasopharynx 16 
T classification  
0 2 
1 26 
2 38 
3 34 
4 21 
N classification  
1 12 
2 93 
3 16 
Smoking history  
Never 39 
Former 49 
Active 33 
Nodal size mean (range) 37.1mm (13mm-150mm) 
Oropharynx 36.6mm (13mm-150mm) 
Nasopharynx 40.3mm (14mm-90mm) 
Treatment technique  
3DCRT 113 
IMRT 8 
Planning intervention 46 
SSD correction 32 
Oropharynx 25 
Nasopharynx 7 
Re-CT 25 
Oropharynx 20 
Nasopharynx 5 
Re-plan 
Oropharynx 
Nasopharynx 
16 
13 
3 
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Table 3 Patient characteristic comparison planning intervention vs no 
planning intervention 
 
Characteristic Intervention SD No intervention SD 
SSD correction n=32  n=89  
Mean T classification 2 1.0 2 1.1 
Mean N classification 2 0.5 2 0.5 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history 
Former smoker - Former smoker - 
Mean nodal size 
(range) 
 
37.8mm*  
(14-70) 
14.2mm* 34.2mm* 
(13-90) 
15.3mm* 
Re-CT n=25  n=96  
Mean T classification 2 1.0 2 1.0 
Mean N classification 2 0.6 2 0.4 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history 
Former smoker - Former smoker   - 
Mean nodal size 
(range) 
 
44.2mm* 
(24-90) 
21.3mm* 32.7mm* 
(13-65) 
11.9mm* 
Re-plan n=16  n=105  
Mean T classification 2 1.2 2 1.0 
Mean N classification 2 0.6 2 0.4 
Mean tumour 
differentiation 
Poorly or 
undifferentiated - 
Poorly or 
undifferentiated - 
Mean smoking 
history Former smoker - Former smoker - 
Mean nodal size 
(range) 
44.8mm*  
(24-90) 21.5mm* 
33.2mm* 
(13-65) 12.8mm* 
* Removal of outlying measurement 
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Table 4 SSD correction details 
 
Detail Number 
Median fraction SSD correction 
accounted for (range) 
26 (5-34) 
Median change in reference separation  
(range) 
1.5cm (0.2cm-2.6cm) 
Mean change in reference separation 1.6cm 
Median change in minimum spinal cord 
separation (range) 
1.6cm (0.2cm-3.4cm) 
Mean change in minimum spinal cord 
separation 
1.6cm 
Correction performed on basis of 
weekly separation measurements 
21 (65.6%) 
Correction performed on basis of re-CT 
information 
11 (34.4%) 
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Table 5 Re-CT details 
 
Detail Number 
No action from re-CT 5 (20%) 
SSD correction based on re-CT 4 (16%) 
Re-plan generated from re-CT 16 (64%) 
IMRT patients 4 (16%) 
Justification for re-CT  
Weight loss 9 
Primary tumour regression 0 
Nodal regression 3 
Combination 11 
Other 2 
Mean initial weight (kg) 82.8 
Mean weight at re-CT (kg) 76.9 
Mean weight loss (%) 7.1 
Mean initial primary GTV (cc) 30.9 
Mean primary GTV at re-CT (cc) 19.9 
Mean primary GTV reduction (%) 35.6 
Mean initial nodal GTV (cc) 59.8* 
Mean nodal GTV at re-CT (cc) 36.8* 
Mean nodal GTV reduction (%) 38.5 
* Removal of outlying measurement 
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